Effects of Naltrexon in patients with Frontal Fibrosing Alopecia

Phase 2

• Conditions: Frontal Fibrosing Alopecia.; Cicatricial alopecia, unspecified; L66.9

• Registration Number: IRCT20230326057776N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

New patients without any other medications
Active status of illness after leaving a systemic medication (at least a month)
Active status of illness while the participants are using a topical medication

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pre-follicular scale. Timepoint: Examinations is done at the beginning of the study and then 2, 4 and 6 months later. Method of measurement: Using Dermoscope.;Erythema. Timepoint: Examinations is done at the beginning of the study and then 2, 4 and 6 months later. Method of measurement: Observiation.;Interfollicular scale. Timepoint: Examinations is done at the beginning of the study and then 2, 4 and 6 months later. Method of measurement: Using a dermoscope.;Decline in frontal and temple hair line. Timepoint: Examinations is done at the beginning of the study and then 2, 4 and 6 months later. Method of measurement: Using a ruler.

Secondary Outcome Measures

Name	Time	Method
Ceasing the progression of disease. Timepoint: Examination is done at the beginning of the study and then 2, 4 and 6 months later. Method of measurement: Frontal Fibrosing Alopecia Severity Index (FFASI).